OverviewSuggest Edit
Celyad is a biopharmaceutical company, specialized in cell therapy and developing of technologies to treat severe diseases with poor prognosis. The Company focuses on immuno oncology, cardiology, and medical devices.
| Type | Public | |
| Founded | 2007 | |
| HQ | Mont-Saint-Guibert, BE | Map |
| Website | celyad.com | |
| Employee Ratings | More |
Recent NewsAll News
- CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
- Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call
- Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial
- Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial
Key People/Management at Celyad
Michel Lussier
Chairman, Non-Executive Director
Filippo Petti
Chief Executive Officer/CFO
Frederic Lehmann
VP Clinical Development and Medical Affairs
Philippe Dechamps
Chief Legal Officer
Philippe Nobels
VP Human Resources
Marina Udier
Independent Director
Celyad Office Locations
Celyad has offices in Mont-Saint-Guibert and New York
Mont-Saint-Guibert, BE (HQ)
2 Rue Edouard Belin
New York, NY, US
60 Broad St Suite 3502
Celyad Financials and Metrics
Celyad Revenue
Celyad's revenue was reported to be €3.54 m in FY, 2017 which is a 58.5% decrease from the previous period.
| EUR | |
|---|---|
Revenue (FY, 2017) | 3.5m |
Revenue growth (FY, 2016 - FY, 2017), % | (58.5%) |
Gross profit (FY, 2017) | 3.0m |
Gross profit margin (FY, 2017), % | 85.5% |
Net income (FY, 2017) | (56.4m) |
EBIT (FY, 2017) | (52.9m) |
Market capitalization (12-May-2022) | 37.5m |
Closing stock price (12-May-2022) | 1.7 |
Cash (31-Dec-2017) | 23.3m |
EV | 14.8m |
Celyad's current market capitalization is €37.5 m.
| EUR | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|
Cash | 100.2m | 48.4m | 23.3m |
Accounts Receivable | 549.0k | 1.4m | 233.0k |
Current Assets | 109.4m | 85.4m | 36.4m |
PP&E | 1.1m | 3.6m | 3.3m |
| EUR | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|
Net Income | (29.1m) | (23.6m) | (56.4m) |
Depreciation and Amortization | 273.0k | 760.0k | 966.0k |
Accounts Payable | 1.1m | (740.0k) | (2.5m) |
Cash From Operating Activities | (27.3m) | (24.7m) | (44.4m) |
| EUR | FY, 2015 |
|---|---|
Financial Leverage | 1.4 x |
Celyad Cybersecurity Score
Celyad Environment, Social & Governance (ESG) Ratings
Celyad Online and Social Media Presence
2.42k Twitter followers
Celyad has 2.42k Twitter Followers. The number of followers has increased 0.1% month over month and increased 0.7% quarter over quarter
Celyad's Trends
Twitter Engagement Stats for @CelyadSA
833
Tweets
651
Following
2.4k
Followers
13
Tweets last 30 days
1.2
Avg. likes per Tweet
76.9%
Tweets with engagement
Celyad News and Updates
May 05, 2022
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the First Quarter 2022 Financial Review section, the figures for cash and cash equivalents and net cash b…
March 17, 2022
Celyad Oncology to Announce Full Year 2021 Financial Results and Host Conference Call
MONT-SAINT-GUIBERT, Belgium, March 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will …
March 02, 2022
Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial
MONT-SAINT-GUIBERT, Belgium, March 02, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that o…
February 28, 2022
Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial
MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it has …
January 10, 2022
Celyad Oncology Provides Outlook for 2022
MONT-SAINT-GUIBERT, Belgium, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced a 2021 year-end review …
December 22, 2021
Celyad Oncology Announces January 2022 Conference Schedule
MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans …
Celyad Blogs
May 17, 2022
Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery
The post Celyad Oncology to Present at the H.C. Wainwright Global Investment Conference appeared first on Celyad Oncology.
May 05, 2022
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
Enrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma
The post Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights appeared first on Celyad Oncolog…
March 25, 2022
Letter to Shareholders – March 2022
Dear Shareholder, Over 2021, the hard work and dedication of the entire Celyad Oncology team has helped us to continue
The post Letter to Shareholders – March 2022 appeared first on Celyad Oncology.
March 24, 2022
Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
Phase 1 IMMUNICY-1 trial demonstrated encouraging data to date for CYAD-211 including a good tolerability profile and evidence of clinical
The post Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights appeared first on Celyad Oncology.
January 31, 2022
Celyad Oncology Announces February 2022 Conference Schedule
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development
The post Celyad Oncology Announces February 2022 Conference Schedule appeared first on Celyad Oncology.
December 17, 2021
Transparency notification received from Tolefi SA and related persons (Article 14 §1 of the Law of 2 May 2007)
Mont-Saint-Guibert, Belgium – 17 December 2021 – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on
The post Transparency notification received from Tolefi SA and related persons (Article 14 §1 of the Law of 2 May 2007) appeared first on Celyad Oncolo…
Celyad Frequently Asked Questions
When was Celyad founded?
Celyad was founded in 2007.
Who are Celyad key executives?
Celyad's key executives are Michel Lussier, Filippo Petti and Frederic Lehmann.
How many employees does Celyad have?
Celyad has 87 employees.
What is Celyad revenue?
Latest Celyad annual revenue is €3.5 m.
What is Celyad revenue per employee?
Latest Celyad revenue per employee is €40.7 k.
Who are Celyad competitors?
Competitors of Celyad include Bellicum Pharmaceuticals, Alnylam Pharmaceuticals and Sorrento Therapeutics.
Where is Celyad headquarters?
Celyad headquarters is located at 2 Rue Edouard Belin, Mont-Saint-Guibert.
Where are Celyad offices?
Celyad has offices in Mont-Saint-Guibert and New York.
How many offices does Celyad have?
Celyad has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies